Summaries of Must-Read Clinical Literature, Guidelines, and FDA Actions
Claims Analysis of Advanced PCa Treatment Costs and Resource Use
Key clinical point: There is a need for appropriate management strategies to optimize the potential delay of disease progression among patients with nonmetastatic CRPC (nmCRPC) because of increased costs.
Major finding: Mean per-patient-per-year all-cause annualized health care costs significantly increased from $35,102.55 in the pre-index nmCRPC period to $156,499.89 after metastasis diagnosis (mCRPC).
Study details: Treatment patterns were assessed in a retrospective cohort study of patients newly diagnosed with mCRPC during pre- and post-index periods; HCRU and costs were annualized for comparison purposes regarding both pre- and post-index timeframes.
Appukkuttan S, et al. Pharmacoecon Open. 2019 Oct 22. doi: 10.1007/s41669-019-00185-8.
